SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                -----------------

                                    FORM 11-K

                                 ANNUAL REPORT
                           PURSUANT TO SECTION 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


(Mark One)
[ X ]             ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES
                  EXCHANGE ACT OF 1934


                   For the fiscal year ended December 31, 2001

                                       OR

[   ]             TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE
                  SECURITIES EXCHANGE ACT OF 1934


           For the transition period from ____________ to ____________


                        Commission File Number 000-14879


            A.  Full title of the plan and the address of the plan, if
                different from that of the issuer named below:


                         CYTOGEN RETIREMENT SAVINGS PLAN


            B.  Name of issuer of the securities held pursuant to the plan
                and the address of its principal executive office:

                               CYTOGEN CORPORATION
                          600 COLLEGE ROAD EAST CN-5308
                            PRINCETON, NJ 08540-5308
                                  (609)750-8200






                         CYTOGEN RETIREMENT SAVINGS PLAN
                   INDEX TO FINANCIAL STATEMENTS AND SCHEDULE

                                DECEMBER 31, 2001




                                                                        Page No.
                                                                        --------
       Required Information....................................................2

       Independent Auditors' Report - KPMG.....................................3

       Report of Independent Public Accountants - Arthur Andersen LLP..........4

       Financial Statements:
          Statements of Net Assets Available for Plan Benefits
             As of December 31, 2001 and 2000..................................5
          Statement of Changes in Net Assets Available for Plan Benefits
             For the Year Ended December 31, 2001..............................6

       Notes to Financial Statements...........................................7

       Supplemental Schedule:
          Schedule H, Part IV, Item i - Schedule of Assets
            Held for Investment Purposes
             As of December 31, 2001..........................................11

       Signature..............................................................12

       Exhibit 23 - Independent Auditors' Consent.............................13









                                      1



                              REQUIRED INFORMATION




1.   Financial  Statements and  Schedule of the Cytogen  Retirement Savings Plan
     prepared in accordance  with the financial  reporting  requirements  of the
     Employee Retirement Income Security Act of 1974, as amended.


Exhibit 23.  Consent of KPMG LLP.










                                       2

  Independent Auditors' Report



To the Plan Administrator
Cytogen Retirement Savings Plan:


We have audited the accompanying statement of net assets available for plan
benefits of Cytogen Retirement Savings Plan (the Plan) as of December 31, 2001,
and the related statement of changes in net assets available for plan benefits
for the year ended December 31, 2001. These financial statements are the
responsibility of the Plan's management. Our responsibility is to express an
opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the net assets available for plan benefits of the Plan as
of December 31, 2001, and the changes in net assets available for plan
benefits for the year ended December 31, 2001, in conformity with accounting
principles generally accepted in the United States of America.

Our audit was performed for the purpose of forming an opinion on the basic
financial statements taken as a whole. The supplemental schedule is presented
for the purpose of additional analysis and is not a required part of the basic
financial statements, but is supplemntary information required by the Department
of Labor's Rules and Regulations for Reporting and Disclosure under the Employee
Retirement Income Security Act of 1974. This supplemental schedule has been
subjected to the auditing procedures applied in the audit of the basic financial
statements and, in our opinion, is fairly stated in all material respects in
relation to the basic financial statements taken as a whole.



                                             /s/ KPMG LLP
                                             --------------------------

Princeton, New Jersey
June 20, 2002


                                       3


THE FOLLOWING AUDIT REPORT IS A COPY OF THE REPORT PREVIOUSLY ISSUED BY ARTHUR
ANDERSEN  LLP ON JULY 23,  2001.  THIS  REPORT HAS NOT BEEN  REISSUED BY ARTHUR
ANDERSEN LLP.



Report of Independent Public Accountants



To the Plan Administrator of
Cytogen Retirement Savings Plan:

We have audited the accompanying statements of net assets available for benefits
of Cytogen Retirement Savings Plan ("the Plan") as of December 31, 2000 and
1999, and the related statement of changes in net assets available for benefits,
and supplemental schedules, for the year ended December 31, 2000. These
financial statements and supplemental schedules are the responsibility of the
Plan's management. Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the net assets available for benefits of the Plan as of
December 31, 2000 and 1999, and the changes in its net assets available for
benefits, and supplemental schedules, for the year ended December 31, 2000, in
conformity with accounting principles generally accepted in the United States.





                                                        /s/ Arthur Andersen LLP
                                                       -------------------------


Philadelphia, Pennsylvania
     July 23, 2001



                                    4




                        CYTOGEN RETIREMENT SAVINGS PLAN

              Statements of Net Assets Available for Plan Benefits

                           December 31, 2001 and 2000


                                                  2001              2000
                                              -----------       -----------
Assets:
  Investments                                 $ 5,266,813       $ 7,486,678
  Participant's contribution receivable            16,990            14,553
  Employer contribution receivable                 47,510            55,909
                                              -----------       -----------
Net assets available for plan benefits        $ 5,331,313       $ 7,557,140
                                              ===========       ===========




See accompanying notes to financial statements.




                                       5



                       CYTOGEN RETIREMENT SAVINGS PLAN

        Statement of Changes in Net Assets Available for Plan Benefits

                          Year Ended December 31, 2001




Net assets available for plan benefits, beginning of year         $   7,557,140
Additions:
  Investment income:
    Interest and dividends                                              107,263
    Interest income from loans                                            1,891
                                                                  --------------
                                                                        109,154
                                                                  --------------
  Contributions:
    Participant                                                         373,167
    Employer                                                            139,946
    Rollovers                                                           176,470
                                                                  --------------
                                                                        689,583
                                                                  --------------

             Total additions                                            798,737
                                                                  --------------

Deductions:
  Net depreciation in fair value of investments                      (1,250,678)
  Benefits paid to participants                                      (1,773,886)
                                                                  --------------
             Total deductions                                        (3,024,564)
                                                                  --------------
             Net decrease                                            (2,225,827)
                                                                  --------------
Net assets available for plan benefits, end of year               $   5,331,313
                                                                  ==============




See accompanying notes to financial statements.





                                       6





                         CYTOGEN RETIREMENT SAVINGS PLAN

                          Notes to Financial Statements

                                December 31, 2001



(1)    Description of the Plan

       (a)    Organization

               The  Cytogen  Retirement  Savings  Plan  (the  Plan) is a defined
               contribution  plan for the employees of Cytogen  Corporation (the
               Employer or the  Company)  that was  established  on December 15,
               1986.  The Plan is governed  by the  provisions  of the  Employee
               Retirement Income Security Act of 1974 (ERISA),  as amended,  and
               is  intended  to comply  with  Sections  401(a) and 401(k) of the
               Internal Revenue Code (IRC).

               The  following  description  of the Plan  provides  only  general
               information. Participants should refer to the Plan document for a
               more complete description of the Plan's provisions.

       (b)    Eligibility

               Each employee  shall become  eligible to  participate  within the
               Plan as of the date when the employee attains the age of 21 years
               and has completed one month of service.

       (c)    Administration

               The  Employer   designates  a  person  or  persons  to  serve  as
               administrator  under the Plan,  who shall perform all such duties
               as are necessary to operate, administer, and manage the Plan. The
               expenses  necessary to administer  the Plan shall be borne by the
               Employer, including necessary professional assistance.

       (d)    Contributions

               Each active  participant may enter into a written salary deferral
               agreement  with the  Employer in which the  employee may elect to
               defer  an  amount  from  1% to 15%  of  his or her  compensation.
               Beginning January 1, 2002, the employee limitation was increased.
               The   Employer,   at   its   discretion,   may  make  a  matching
               contribution in an amount up to 50% of the employee contribution,
               not to exceed limitations set forth by the Plan. The Employer may
               also make an annual Employer discretionary contribution under the
               Plan in an amount that the  Employer's  Board of Directors  shall
               determine by  resolution.  The  allocation of this  discretionary
               contribution   shall   be  made  in  the   proportion   that  the
               compensation paid to each participant  during the Plan year bears
               to the  compensation  paid to all such  participants,  subject to
               limitation  set forth by the Plan.  The Employer has the  ability
               to make discretionary matching  contributions in  cash or Cytogen
               Common Stock.

               The Plan also permits the rollover of cash transferred from other
               employee  benefit  plans  which  are  qualified  under  the  IRC.
               Rollovers of cash are included as part of asset  additions in the
               statement of changes in net assets  available for  benefits.  For
               the year ended  December 31, 2001,  rollovers of cash amounted to
               $176,470.

       (e)    Vesting and Forfeitures

               A participant's interest in the Employer matching contribution is
               100% vested upon the  contribution  for employees  hired prior to
               January 1, 2000.  Employees  hired after that date are subject to
               four year vesting of any Employer  contribution.  Vesting  credit
               shall be given for each year of service, except plan years during
               which a  participant  did not  complete  at least  1,000 hours of
               service. If a participant  terminates  employment and is not 100%
               vested, the nonvested portion of the participant's  account shall
               be placed in a separate account and will become a forfeiture upon
               the date such terminated  participant  incurs a one-year break in
               service.  These  forfeitures  shall  be used by the  Employer  to
               reduce the Employer's contribution.

                                       7



                         CYTOGEN RETIREMENT SAVINGS PLAN

                          Notes to Financial Statements

                                December 31, 2001



       (f)    Distributions/Benefits

               A participant who attains the normal  retirement age shall have a
               vesting  percentage of 100%.  If a  participant  retires from the
               active  service of the  Employer on the normal  retirement  date,
               then he or she shall receive a  distribution  of the entire value
               of their  vested  participant  account  or may  elect an  annuity
               distribution  as  permitted  under the Plan.  A  participant  who
               retires from the service of the Employer on account of disability
               shall  have a  vesting  percentage  of 100% and  shall  receive a
               distribution of the entire value of their participant account.

       (g)    Participant Loans

               All   participants   in  the  Plan  may  obtain,   under  certain
               conditions,  a loan secured by the participant's account balance.
               The  amount of all  outstanding  loans to a  participant  may not
               exceed 50% of the participant's vested account balance. The loans
               are made at a rate  equivalent to rates charged by a professional
               lender in a  similar  circumstance.  Loans are  repaid in no more
               than five  years,  except if the loan is for the  purchase of the
               participant's  primary  residence,  in which  case the  repayment
               period may exceed five years.

       (h)    Investment Options



                          Fund                                           Objective
           -----------------------------------    -----------------------------------------------------
                                               
           MFS Emerging Growth Fund               Invests in emerging growth companies, foreign and
                                                  emerging market securities, and derivative securities.

           MFS Money Market Fund                  Invests in a broad range of money market instruments.

           Massachusetts Investor Trust           Invests in stock, foreign and emerging market

           Massachusetts Investor Growth Stock    Invests in long-term growth companies, foreign and
           Fund                                   emerging market securities, and derivative securities.

           MFS Research Fund                      Invests in a broad range of stocks.

           MFS Total Return Fund                  Invests in fixed-income securities, stocks, and derivative
                                                  securities.

           MFS High Income Fund                   Invests in high yield corporate bonds, high yield
                                                  securities, and foreign and emerging market
                                                  securities.

           MFS Capital Opportunities Fund         Invests in moderate growth companies, foreign and
                                                  emerging market securities, and derivative securities.

           MFS Government Securities Fund         Invests in fixed-income government securities and
                                                  derivative securities.


                                       8



                         CYTOGEN RETIREMENT SAVINGS PLAN

                          Notes to Financial Statements

                                December 31, 2001





                          Fund                                           Objective
           -----------------------------------    -----------------------------------------------------
                                               
           MFS Global Equity Fund                 Invests in common stocks and equivalents, foreign
                                                  and emerging market securities, and derivative
                                                  securities.

           MFS Fixed Fund                         Invests in stable-value investment contracts.

           MFS Mid Cap Growth Fund                Invests in growth stocks of mid-capitalization
                                                  companies.

           MFS Value Fund                         Invests in undervalued, income-producing stocks with
                                                  capital appreciation potential.

           MFS Technology Fund                    Invests in equity securities of companies of any size
                                                  that have above-average growth potential and will
                                                  benefit from technological advances and
                                                  improvements.


       (i)    Termination

               As of a  participant's  termination of employment,  they shall be
               entitled  to  receive  a  distribution  of  their  entire  vested
               interest. Such distribution shall be further subject to terms and
               conditions set forth by the Plan.

(2)    Summary of Significant Accounting Policies

       (a)    Basis of Accounting

               The Plan is subject to the provisions of the Employee  Retirement
               Income Security Act of 1974, as amended (ERISA). The accompanying
               financial  statements  have been prepared on the accrual basis of
               accounting,  except for distributions that are accounted for on a
               cash  basis in  accordance  with the AICPA  Audit and  Accounting
               Guide entitled Audits of Employee Benefit Plans.  Investments are
               stated at market value.

       (b)    Use of Estimates

               The  preparation  of  financial  statements  in  conformity  with
               accounting  principles  generally  accepted  in the United States
               requires management to make estimates and assumptions that affect
               the financial  statements and the related  disclosures during the
               reporting   period.   Actual  results  could  differ  from  those
               estimates.

                                       9



                         CYTOGEN RETIREMENT SAVINGS PLAN

                          Notes to Financial Statements

                                December 31, 2001



       (c)    Valuation of Investments

               Investments  represent  units in a series of funds managed by the
               investment  manager.  The Plan's  investment  funds are stated at
               market  value,  as  determined  based  on  market  quotes  of the
               underlying assets.

       (d)    Plan Expenses

               All  administrative  costs  associated  with the operation of the
               Plan are paid by the Employer in accordance with the terms of the
               Plan.

       (e)    Purchases and Sales of Securities

               Purchases and sales of  securities are  recorded on a  trade date
               basis.

(3)    Investments

          The following  table presents the current values of individual  assets
          that  represent  5% or more of the  Plan's net  assets  available  for
          plan benefits as of December 31, 2001 and 2000 as follows:

          Description/Issuer of Investment                2001           2000
          ----------------------------------------    -----------     ----------
          MFS Emerging Growth Fund                    $  433,869      $  808,246
          Massachusetts Investor Trust                   324,116         620,564
          Massachusetts Investor Growth Stock Fund     1,096,579       2,260,178
          MFS Research Fund                              384,914         689,687
          MFS Capital Opportunities Fund                 577,702         897,482
          MFS Government Securities Fund                 667,617         965,414
          MFS Global Equity Fund                         349,929         398,032
          MFS Fixed Fund                                 877,372         604,113


(4)    Tax Status

          The trust  established  under the Plan is  qualified  under the IRC as
          exempt from federal  income  taxes.  The Plan has received a favorable
          determination  letter  from the IRS but has not been  updated  for the
          most recent plan amendment.  However,  the plan  administrator and the
          Plan's tax counsel  believe  that the plan is  currently  designed and
          being operated in compliance  with the applicable  requirements of the
          IRC.  Therefore,  they  believe  that the Plan was  qualified  and the
          related trust was tax-exempt as of the financial statement date.

(5)    Plan Termination

          Although it has not expressed any intent to do so, the Company has the
          right under the Plan to discontinue its  contributions  at anytime and
          to terminate  the Plan,  subject to the  provisions  of ERISA.  In the
          event of termination,  distributions shall be subject to the terms and
          conditions set forth by the Plan.

(6)    Distributions/Benefits Paid to Participants

          Distributions/benefits  paid to  participants  are generally made on a
          monthly  basis for those  requests  processed in the  previous  month.
          There were no distributions/benefits payable to the participants as of
          December 31, 2001.


                                       10





                        CYTOGEN RETIREMENT SAVINGS PLAN

   Schedule H, Part IV, Item i Schedule of Assets Held for Investment Purposes

                                December 31, 2001



                                                              Market
           Description of investment                           value
--------------------------------------------------        --------------
MFS Emerging Growth Fund                                   $   433,869
MFS Money Market Fund                                           35,695
Massachusetts Investor Trust                                   324,116
Massachusetts Investor Growth Stock Fund                     1,096,579
MFS Research Fund                                              384,914
MFS Total Return Fund                                          216,357
MFS High Income Fund                                            40,388
MFS Capital Opportunities Fund                                 577,702
MFS Government Securities Fund                                 667,617
MFS Global Equity Fund                                         349,929
MFS Mid-Cap Growth Fund                                         38,352
MFS Fixed Fund                                                 877,372
MFS Value Fund                                                 124,218
MFS Technology Fund                                             28,251
CYTOGEN Corporation Stock Fund*                                 71,454
                                                           -----------
Total investments held at end of year                      $ 5,266,813
                                                           ===========

* Party-in-interest investment






                                       11



     After  reasonable  efforts,  we have not been  able to obtain  the  written
consent  of Arthur  Andersen  LLP ("Arthur  Andersen") to our  incorporation  by
reference  into the Cytogen  Retirement  Savings Plan (the "Plan")  Registration
Statement on Form S-8 (File No.  333-59718)  of Arthur  Andersen's  report dated
July 23,  2001  relating to the Plan's  financial  statements  and  supplemental
schedules  included  in this  Annual  Report  on Form  11-K for the  year  ended
December 31, 2000.  Therefore,  we have dispensed  with the  requirement to file
their consent in reliance on Rule 437a  promulgated  under the  Securities  Act.
Because Arthur  Andersen has not consented to the inclusion of its report in the
Registration Statement on Form S-8 (File No. 333-59718),  your ability to assert
claims against Arthur  Andersen may be limited.  In particular,  because of this
lack of  consent,  you will not be able to sue  Arthur  Andersen  under  Section
11(a)(4) of the  Securities  Act for any untrue  statements  of a material  fact
contained  in  the  financial  statements  audited  by  Arthur  Andersen  or any
omissions  to state a material  fact  required  to be stated in those  financial
statements  and  therefore  your right of  recovery  under that  section  may be
limited.



                                    SIGNATURE



THE PLAN

Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the Plan
has duly caused this annual report to be signed on its behalf by the undersigned
hereunto duly authorized.

                                       CYTOGEN RETIREMENT SAVINGS PLAN


                                     By: Cytogen Corporation, Plan Trustee


Date:     June 27, 2002              By:    /s/ H. Joseph Reiser
       ------------------------          ---------------------------------------
                                         H. Joseph Reiser
                                         President and Chief Executive Officer








                                      12